M
Martin R. Farlow
Researcher at Indiana University
Publications - 431
Citations - 29686
Martin R. Farlow is an academic researcher from Indiana University. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 82, co-authored 381 publications receiving 26820 citations. Previous affiliations of Martin R. Farlow include Southern Illinois University School of Medicine & Saint Louis University.
Papers
More filters
Journal ArticleDOI
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
TL;DR: The data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD.
Journal ArticleDOI
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
Maria Grazia Spillantini,Jill R. Murrell,Michel Goedert,Martin R. Farlow,Aaron Klug,Bernardino Ghetti +5 more
TL;DR: The results show that dysregulation of tau protein production can cause neurodegeneration and imply that the FTDP-17 gene is the tau gene, which has major implications for Alzheimer's disease and other tauopathies.
Journal ArticleDOI
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody,Ronald G. Thomas,Martin R. Farlow,Takeshi Iwatsubo,Bruno Vellas,Steven Joffe,Karl Kieburtz,Rema Raman,Xiaoying Sun,Paul S. Aisen,Eric Siemers,Hong Liu-Seifert,Richard C. Mohs +12 more
TL;DR: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with mild Alzheimer's disease.
Journal ArticleDOI
A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease.
TL;DR: Direct sequencing of DNA from a family with autopsy-proven Alzheimer's disease revealed a single amino acid substitution (Phe for Val) in the transmembrane domain of the amyloid precursor protein, which may be the inherited factor causing both amyloids fibril formation and dementia.
Journal ArticleDOI
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Rachelle S. Doody,Rema Raman,Martin R. Farlow,Takeshi Iwatsubo,Bruno Vellas,Steven Joffe,Karl Kieburtz,Feng He,Xiaoying Sun,Ronald G. Thomas,Paul S. Aisen,Eric Siemers,Gopalan Sethuraman,Richard C. Mohs +13 more
TL;DR: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability, and semagACestat was associated with more adverse events, including skin cancers and infections.